Evidence map›Paper›PMID 35466329›Full record

ArticleAdvances in geriatric medicine and research2022

Near-Lifespan Tracking of Cerebral Microvascular Degeneration in Aging to Alzheimer's Continuum.

Jonghwan Lee

Open access · diamondAbstract read
In one paragraph

Article in Advances in geriatric medicine and research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jonghwan LeeCenter for Biomedical Engineering, School of Engineering, Brown University, Providence, RI 02912, USA.
Allen Institute for Brain Science · US

Funding

Long-Term Tracking of Cerebral Microvascular Structural and Functional Alterations between Normal and Alzheimer's AgingR01AG067228 · NIA · BROWN UNIVERSITY · PI LEE, JONGHWAN · 2020 to 2024
$1.8M
NIA NIH HHS R01 AG067228
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting millions of people worldwide and is currently incurable. As the population ages, AD and related dementia are becoming the biggest epidemic in medical history: the number of people aged 65 and older with AD is projected to increase between two- and three-fold by 2050. Imaging and biomarker studies suggest that the pathophysiological processes of AD begin more than a decade before the diagnosis of dementia, opening the possibility of early, preemptive prediction. For accurate prediction, it is important although challenging to fully understand how multiple etiologies and age-related prodromal processes contribute to the onset of Alzheimer's continuum, across a long period comparable to the lifespan. Addressing this challenge was one of the overarching transformative concepts at the 2015 AD Research Summit, "to develop new programs on

Indexed as

Alzheimer’s diseaseintegrative pathophysiologylongitudinal trackingmicrovascular degenerationvascular factor

Identifiers

PMID35466329
PMCPMC9022674
OpenAlexW4226307399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.